Qing Ma PharmD, PhD

Qing Ma

Qing Ma
PharmD, PhD

Associate Professor

Department of Pharmacy Practice

School of Pharmacy


Specialty/Research Focus

Academia; Anti-Platelet Therapy and Anticoagulation; Blood-Brain Barrier and Brain Delivery; Clinical Research; HIV; Infectious Disease; Neuropharmacology; Pharmacogenomics; Pharmacokinetics; Toxicology

Contact Information
Department of Pharmacy Practice
School of Pharmacy and Pharmaceutical Sciences
315 Pharmacy Building
Buffalo, NY 14214-8033
Phone: (716) 881-7500
Fax: NA
qingma@buffalo.edu



Professional Summary:

Dr. Ma has focused his research on pharmacotherapy of HIV-associated neurocognitive disorders. With a longer life expectancy, people living with long-term HIV infection exhibit clinical manifestations of aging early, such as multimorbidity, polypharmacy, and decline in cognitive abilities. Dr. Ma has developed a broad research program that has expanded and evolved into investigating pharmacokinetics and pharmacodynamics of antiretroviral therapy on the central nervous system, pharmacogenomics, drug-drug interactions, and polypharmacy in relation to neurocognitive function in the elderly living with HIV. His research projects involve a multidisciplinary team that encompasses pharmacy, clinical pharmacology, neurology, psychology, substance use disorders, and biomarker disciplines and utilize a variety of data and laboratory analytical techniques as well as cell culture and small animal models through collaborations.

Education and Training:

  • PharmD, University of Colorado (2017)
  • PhD, Loyola University Chicago (2003)
  • BS, West China University of Medical Sciences (1995)

Employment:

  • Associate Professor of Pharmacy Practice, Pharmacy Practice, University at Buffalo (2019-present)
  • Adjunct Professor of Pharmacology and Physiology, University of Rochester (2012-present)
  • Research Scientist, Translational Pharmacology Research Core, University at Buffalo, New York State Center of Excellence in Bioinformatics and Life Sciences (2006-present)
  • Assistant Professor of Pharmacy Practice, Pharmacy Practice, University at Buffalo (2013–2019)
  • Research Assistant Professor, University at Buffalo (2006–2013)
  • Fellow, University at Buffalo (2004–2005)

Awards and Honors:

  • Research Mentor of the Year (2012)
  • Visiting Scholar (2010)
  • Visiting Professor (2008)
  • Conference Scholarship (2007)
  • George McCracken Infectious Disease Fellow (2005)
  • George McCracken Infectious Disease Fellow (2004)
  • Travel Award (2004)
  • Young Investigator Award (2003)
  • Graduate Travel Award (2002)

Research Centers:

  • Clinical and Translational Research Center (CTRC)
  • Center of Excellence in Bioinformatics and Life Sciences

UB 2020 Strategic Strengths:

  • Health and Wellness Across the Lifespan

Grants and Sponsored Research:

  • May 2020–February 2025
    Aging, Polypharmacy and Neurotoxicity in Adults Living with HIV
    National Institute on Aging
    Role: Co-Principal Investigator
    $1,655,185
  • June 2012–June 2017
    Antiretroviral pharmacogenomics, pharmacokinetics and toxicity in neuroAIDS
    NIH
    Role: Principal Investigator
    $598,880

Journal Articles:

See all (41 more)

Abstracts:

  • Mudzviti T; Maponga C; Khoza S; Tagwireyi D; Ma Q; Morse ED. Adverse Drug Reactions During Antiretroviral Therapy in Zimbabwe. 37th Annual International Conference on Global Health. 2010.
  • Maponga C; DiFrancesco R; Tooley KM; Jaravani P; Ma Q; Morse ED. Establishing an AIDS International Training and Research Program (AITRP) to Increase Capacity for HIV Clinical Pharmacology Research In Southern African Countries. 18th International AIDS Conference (AIDS 2010). 2010.
  • Venuto C; Ma Q; Morse ED. Effects of CYP2B6 single nucleotide polymorphism (SNPs) and substance abude on efavirenz (EFV) pharmacokinetics. UB Celebration of Academic Excellence. 2010.
  • Ma Q; Tooley KM; Welliver R; Condino D; Lliguicota F; Maponga C; DiFrancesco R; Morse ED; Sulaimen A; Felton C; Sawyer JR; Mudzviti T; Hsiao CB; Walshe K; Gbadamosi F; Sayidine F. Developing an International Health Information Technology Network for HIV Medication Management Research. NY HIV Research Centers Consortium. 2010.
  • Venuto C; Morse ED; Ma Q; Brazeau D; Zingman B; Reichman RC; Fischl M; Gripshover B; DiFrancesco R; Forrest A. Effects of CYP2B6 Single Nucleotide Polymorphisms (SNPs) and Substance Abuse on Efavirenz (EFV) Pharmacokinetics. ICAAC Conference. 2009.
  • Acheampong F; Morse ED; Ma Q; Brazeau D; Zingman B; Reichman R; Fischl M; Gripshover B; DiFrancesco R; Forrest A. Relationship between CYP3A5 Nucleotide Polymorphisms and Protease Inhibitor Trough Concentrations in HIV+ Patients during Therapeutic Drug Monitoring. ICAAC Conference. 2009.
  • Fehintola F; Ma Q; Zingman B; Reichman R; Fischl M; Gripshover B; DiFrancesco R; Forrest A; Morse ED. Tobacco and Marijuana Uses Significantly Decrease Atazanavir (ATV) Trough Concentrations in HIV Infected Individuals. ICAAC Conference. 2009.
  • Ma Q; Forrest A; Rosenkranz S; Para M; Adams E; Yaresheski K; Reichman RC; Morse ED; A. Optimal multidrug PK and sampling strategies (OSS) for efavirenz and indinavir. 2005 Annual Meeting of the American Society of Clinical Pharmacology & Therapeutics. 2005.
  • Zack J; A; Forrest A; Ma Q; Rosenkranz S; Para MF; Adams E; Yaresheski K; Reichman RC; Morse ED. Optimal Sparse Pharmacokinetic Sampling Strategies for Multi-Drug Antiretroviral Regimens. Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics. 2005.

Professional Memberships:

  • American Association of Colleges of Pharmacy (2010–present)
  • International AIDS Society (2006)
  • American Society of Microbiology (2004)
  • American College of Clinical Pharmacy (2004–present)
  • Society of Infectious Diseases Pharmacists (2004)
  • American Society for Clinical Pharmacology and Therapeutics; Award Committee Member, Education Committee Member (2001)
  • American Society for Pharmacology and Experimental Therapeutics (2000–present)
  • American Society for Clinical Pharmacology and Therapeutics (2000–present)
  • American Pharmacist Association (1999)

Presentations:

  • "Broadly Neutralizing Antibodies: a Road to Functional Cure of HIV" 2021 Forbidden City International Pharmacist Forum, Forbidden City International Pharmacist Forum, Infectious Disease Pharmacy (2021)
  • "Polypharmacy and the Brain: An Old Story" 2021 Forbidden City International Pharmacist Forum, Forbidden City International Pharmacist Forum, Geriatric Pharmacy (2021)
  • "Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202)" XIX International AIDS Conference, IAS AIDS (2012)
  • "Tenofovir Plasma Pharmacokinetics in AIDS Clinical Trials Group Study A5202" XIX International AIDS Conference (AIDS/IAS 2012), IAS AIDS (2012)
  • "Comparison of modeled and non-modeled clearances for efeavirenz" Translational Science 2012 (2012)
  • "Pharmacogenomics of CYP3A: Considerations for HIV Treatment" 5th Health Disparities Conference, Xavier University of Louisiana (2012)
  • "A Physiological Pharmacokinetic Model Characterizes Efavirenz Metabolic Induction in HIV-Infected Ugandan Patients" 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (2011)
  • "Pharmacokinetics of efavirenz among HIV infected Ugandans" 12th International Workshop on Clinical Pharmacology of HIV Thearpy (2011)
  • "Establishing A Health Information Technology Network for HIV/TB Medication Management Research" 2nd Annual World AIDS Day Scientific Symposium, University of Rochester (2010)
  • "Interindividual Variability of ABCB1 Expression in Peripheral Blood Mononuclear Cells from HIV-Infected Patients" 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (2010)
  • "Developing an International Health Information Technology Network for HIV Medication Management Research" 2010 Scientific Conference New York HIV Research Centers Consortium (2010)
  • "Update on pharmacotherapy for pediatric HIV infection" 13th Asian Pacific Congress of Pediatrics (2009)
  • "Effects of CYP2B6 single nucleotide polymorphisms and substance abuse on efavirenz pharmacokinetics" 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM (2009)
  • "Inter-individual variability of atazanavir plasma concentrations in HIV patients" 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM (2009)
  • "Relationship between CYP3A5 single nucleotide polymorphisms and protease inhibitor trough concentrations in HIV+ patients during therapeutic drug monitoring" 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM (2009)
  • "Tobacco and marijuana uses significantly decrease atazanavir trough concentrations in HIV infected individuals" 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM (2009)
  • "Comparison of antiretroviral pharmacokinetics and clinical monitoring parameters in HIV-infected patients with and without substance abuse" 16th Conference on Retroviruses and Opportunistic Infections (2009)
  • "Clinical and Translational Pharmacogenomics: Integrating a Seminar Program with UndergraduatePharmacogenomics Research" American College of Clinical Pharmacy 2008 Annual Meeting, American College of Clinical Pharmacy (2008)
  • "Determining the rate, nature and predictors of adverse drug reactions associated with the use of highly active antiretroviral therapy (HAART) in a resource limited setting (Zimbabwe)" IX World Conference on Clinical Pharmacology and Therapeutics (2008)
  • "Effect of CYP3A5 polymorphisms on atazanavir and lopinavir trough concentrations in HIV-infected substance abusers" 9th International Workshop on Clinical Pharmacology of HIV Therapy (2008)
  • "An Appropriate Structural and Population Pharmacokinetic (PK) Model for Atazanavir (ATV)" 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (2007)
  • "Therapeutic Drug Monitoring and Inhibitory Quotients in HIV-Infected Substance Users and Non-substance Users Receiving HIV-1 Protease Inhibitors" 14th Conference on Retroviruses and Opportunistic Infections (2007)
  • "CYP3A5 polymorphisms in HIV-infected substance users and nonusers during therapeutic drug monitoring" 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006)
  • "MDR1 Single Nucleotide Polymorphisms in HIV-infected Substance Users and Nonusers during Therapeutic Drug Monitoring" 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005)
See all (14 more)

Service Activities:

  • Volwiler Research Achievement Award Committee; Committee Member (2021–present)
  • Program Committee American Society for Pharmacology and Experimental Therapeutics; Committee Member (2021–present)
  • Division of Toxicology American Society for Pharmacology and Experimental Therapeutics; Councilor (2020–present)
  • Neurology Collaborative Science Group Scientific Committee; AIDS Clinical Trip Group; Member (2012)
  • Chinese Clinical Pharmacy Collaboration; Communication between Chinese pharmacy schools and UB, development of MOU; Coordinator (2011)
  • Education Committee; American Society for Clinical Pharmacology and Therapeutics Education Committee Award Committee; Other (2008)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

Department of Pharmacy Practice
School of Pharmacy and Pharmaceutical Sciences
315 Pharmacy Building
Buffalo, NY 14214-8033
Phone: (716) 881-7500
Fax: NA
qingma@buffalo.edu